Form 4: Cognex Corp Executive Matthew Moschner Reports Stock Option Grant
SEC Form 4 Filing
Matthew Moschner, President and COO of Cognex Corp, reports the acquisition of stock options and adjustments to his holdings of common stock and derivative securities.
Summary
- On May 7, 2025, Matthew Moschner, President and COO of Cognex Corp, filed a Form 4.
- The report details changes in his beneficial ownership of Cognex Corp securities.
- Moschner acquired 279,070 non-qualified stock options with an exercise price of $27.99, exercisable from May 5, 2029, to May 5, 2035.
- He also reported owning 3,812 shares of common stock directly.
- The filing includes details of various other non-qualified stock options and restricted stock units (RSUs) held by Moschner, with different exercise prices, vesting dates, and expiration dates.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it is a routine disclosure of stock option grants. It reflects standard executive compensation practices.
Positives
- The grant of stock options to the President and COO aligns his interests with those of the shareholders.
- The vesting schedule of the options encourages long-term commitment from the executive.
Industry Context
Executive compensation through stock options is a common practice in the technology industry to incentivize performance and align management's interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the tech industry, similar to companies like Keyence, Omron, and Teledyne Technologies.
- The vesting schedules and exercise prices are generally in line with industry norms for companies of Cognex's size and market capitalization.
- The specific terms of the options, such as the vesting period and expiration date, are tailored to the individual executive's role and performance expectations.
Stakeholder Impact
- The stock option grant aligns the executive's interests with shareholders, potentially driving long-term value creation.
- Employees may view the grant positively as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/20/2019 | Non-Qualified Stock Option (right to buy) $ 56.44 |
| 11/19/2019 | Non-Qualified Stock Option (right to buy) $ 40.71 |
| 02/19/2020 | Non-Qualified Stock Option (right to buy) $ 51.49 |
| 10/30/2020 | Non-Qualified Stock Option (right to buy) $ 51.97 |
| 10/31/2021 | Non-Qualified Stock Option (right to buy) $ 42.84 |
| 08/04/2023 | Restricted Stock Unit $ 0.0 |
| 02/21/2024 | Non-Qualified Stock Option (right to buy) $ 47.21 and Restricted Stock Unit $ 0.0 |
| 08/07/2024 | Restricted Stock Unit $ 0.0 |
| 02/20/2025 | Restricted Stock Unit $ 0.0 |
| 05/05/2025 | Date of Earliest Transaction and Non-Qualified Stock Option (right to buy) $ 27.99 |
| 08/09/2025 | Non-Qualified Stock Option (right to buy) $ 86.38 |
| 02/18/2026 | Non-Qualified Stock Option (right to buy) $ 33.04 and Restricted Stock Unit $ 0.0 |
| 08/04/2026 | Non-Qualified Stock Option (right to buy) $ 47.95 |
| 08/07/2027 | Non-Qualified Stock Option (right to buy) $ 50.01 |
| 05/07/2025 | Date of filing the Form 4 |
Keywords
Form 4, Cognex Corp, Matthew Moschner, Stock Options, Beneficial Ownership, Securities, Executive Compensation, CGNX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.